Treatment of estrogen deficiency symptoms in women surviving breast cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 6, 1998, Pages 1993-2000

  Santen, Richard J ^a,p   Anderson, Tom ^b   Bardin, C Wayne ^c   Barrett Conner, Elizabeth ^d   Black, Catherine ^e   Borwhat, Margaret ^f   Burger, Henry ^g   Clarkson, Thomas ^h   Cobleigh, Melody ⁱ   Cosman, Felicia ^j   Douglas, Mary Sue ^e   Dunaif, Andrea ^k   Ford, Jane ^l   Ganz, Patricia ^m   Gleason, Sally ^l   Goodwin, Pamela ⁿ   Goss, Paul ^e   Green, Bettye ^l   Gretz, Elissa ^o   Harvey, Jennifer ^p   Hazzard, William ^h   Helzlsouer, Kathy ^q   Jordan, V Craig ^r   Josse, Robert ^s   Kelaghan, Joseph ^t   Kleerekoper, Michael ^u   Lewis, Jacqueline ^s   Llewellyn Thomas, Hilary ^s   Loprinzi, Charles ^v   Mark, Meryl ^w   Martin, Andrea ^x   Martin, Hugette ^e   Miesfeldt, Susan ^p   Moore, Marcia ^p   Nachtigall, Lisa ^y   New, Maria ^z   O'Connor, Annette ^aa   Olsen, Mark ^ab   Parker, Barbara ^ac   Parnes, Howard ^t   Perlman, Jeffrey ^ad   Pinkerton, Joann ^p   Powles, Trevor ^ae   Prior, Jerilynn ^af   Pritchard, Kathleen ^s   Ragaz, Joseph ^ag   Railey, Elda ^ah   Rumen, Nina ^e   Ropka, Mary ^p   Ross, Ron K ^ai   Sawka, Carol ^s   Sellin, Rena ^aj   Slingluff, Craig ^p   Swain, Sandra ^ak   Tysenhouse, Phyllis ^al   Watts, Nelson ^am   Whamond, Elizabeth ^e   Wills, Michael ^p   more..

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NICHD   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Patient Advocate Foundation ^*

^f Patient Advocate Foundation   (United States)

^g HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k HARVARD UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m Pediatric Oral and Maxillofacial Surgery   (Canada)

ⁿ UNIVERSITY HEALTH NETWORK   (Canada)

^o Department of Obstetrics Gynecology   (United States)

^p UNIVERSITY OF VIRGINIA   (United States)

^q JOHNS HOPKINS UNIVERSITY   (United States)

^r NORTHWESTERN UNIVERSITY   (United States)

^s UNIVERSITY OF TORONTO   (Canada)

^t NATIONAL CANCER INSTITUTE   (United States)

^u WAYNE STATE UNIVERSITY   (United States)

^v MAYO CLINIC   (United States)

^w New York School of Medicine   (United States)

^x Breast Cancer Fund   (United States)

^y Family Practice Residency Program   (United States)

^z WEILL CORNELL MEDICAL CENTER   (United States)

^aa UNIVERSITY OF OTTAWA   (Canada)

^ab St Luke's Sinai Samaritan Med C   (United States)

^ac Breast Cancer Coal of N Carolina   (United States)

^ad Epimedix   (United States)

^ae Royal Marsden Hospital   (United Kingdom)

^af UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^ag BRITISH COLUMBIA CANCER AGENCY   (Canada)

^ah Susan G Komen Foundation   (United States)

^ai UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^aj UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ak Virginia Breast Cancer Foundation ^*  (United States)

^al Virginia Breast Cancer Foundation   (United States)

^am EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER RESEARCH; CORONARY RISK; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HUMAN; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0000722701     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.6.4934     Document Type: Review

References (44)

1. Adami H-O, Persson I. 1995 Hormone replacement and breast cancer: a remaining controversy? JAMA. 274:178-179.
2. Ayton RA, Darling GM, Murkies AL, et al. 1996 A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol. 103:351-358.
3. Bergkvist L, Persson I. 1996 Hormone replacement therapy and breast cancer. A review of current knowledge. Drug Safety. 15:360-370.
4. Bines J, Oleske DM, Cobleigh MA. 1996 Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 14:1718-1729.
5. Birge SJ. 1997 The role of estrogen in the treatment and prevention of dementia. Am J Med. 103:1S-50S.
6. Calle EE, Miracle-McMahill HL, Thun MJ, Heath Jr CW. 1995 Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Nat Cancer Inst. 87:517-523.
7. Chang J, Powles TJ, Ashley SE, et al. 1996 The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density, and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study. Ann Oncol. 7:671-675.
8. Chesnut CH, McClung MR, Ensrud KE, et al.1995 Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 99:144-152.
9. Cobleigh MA, Berris RF, Bush T, et al. 1994 Estrogen replacement therapy in breast cancer survivors. A time for change. JAMA. 272:540-545.
10. Col NF, Eckman MH, Karas RH, et al. 1997 Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 277:1140-1147.
11. Colditz GA, Hankinson SE, Hunter DJ, et al. 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women N Engl J Med. 332:1589-1593.
12. Couzi RJ, Helzlsouer KJ, Fetting JH. 1995 Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 13:2737-2744.
13. Darling GM, Johns JA, McCloud PI, Davis SR. 1997 Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med. 337:595-601.
14. Davidson NE. 1995 Hormone-replacement therapy - breast versus heart versus bone. N Engl J Med. 332:1638-1639.
15. Delmas PD, Bjarnason NH, Mitlak BH, et al. 1997 Effects of Raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1641-1647.
16. Disaia PJ. 1997 Estrogen replacement therapy for the breast cancer survivor: a reappraisal. J Surg Oncol. 64:175-180.
17. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. 1946 A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 11:835-842.
18. Fisher B, Dignam J, Bryant J, et al. 1496 Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Nat Cancer Inst. 88:1529-1542.
19. Grady D, Rubin SM, Petitti DB, et al. 1992 Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1016-1037.
20. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. 1994 Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 12:155-158.
21. Gotto Jr AM. 1997 Results of recent large cholesterol-lowering trials and implications for clinical management. Am J Cardiol. 79:1663-1666.
22. Grey AB, Stapleton JP, Evans MC, Reid IR. 1995 The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab. 80:3191-3195.
23. Grodstein F, Stampfer MJ, Colditz GA, et al. 1997 Postmenopausal hormone therapy and mortality. N Engl J Med. 336:1769-1775.
24. Handa VL, Bachus KE, Johnston WW, Robboy SJ , Hammond CB. 1494 Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol. 84:215-218.
25. Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. 1996 A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 174:85-92.
26. Kjekshus J, Pedersen TR. 1995 Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study. Am J Cardiol. 76:64C-68C.
27. Liberman UA, Weiss SR, Broll J, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1437-1443.
28. Lindsay R, Bush TL, Grady D, Speroff L, Lobo R. 1996 Therapeutic controversy: estrogen replacement in menopause. J Clin Endocrinol Metab. 81:3829-3838.
29. Loprinzi CL, Michalak JC, Quella SK, et al. 1994 Megestrol acetate for the prevention of hot flashes. N Engl J Med. 331:347-352.
30. Loprinzi, CL, Abu-Ghazaleh S , Sloan JA, et al. 1997 Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 15:969-973.
31. Love RR, Mazess RB, Barden HS, et al. 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326:852-856.
32. Mitlak BH, Cohen FJ. 1947 In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res. 48:155-163.
33. Nagamani M, Kelver ME, Smith ER. 1987 Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol. 156:561-565.
34. Overgaard K, Hansen MA, Jensen SB, Christiansen C. 1992 Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J. 305:556-561.
35. PEPI Trial Group. 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 273:199-208.
36. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. 1996 Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 14:78-84.
37. Reginster JY, Deroisy R, Lecart MP, et al. 1995 A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med. 98:452-458.
38. Roy JA, Sawka CA, Pritchard KI. 1996 Hormone replacement therapy in women with breast cancer: do the risks outweigh the benefits? J Clin Oncol. 14:997-1006.
39. Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I. 1996 Anti-atherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol. 14:429-433.
40. Sawka CA, Pritchard KI, Paterson AH, et al. 1986 Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res. 46: 3152-3156.
41. Shepherd J, Cobbe SM, Ford I, Isles CG, et al. 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med. 333:1301-1307.
42. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. 1994 Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology. 5:415-421.
43. Trichopoulos D, MacMahon B, Cole P. 1972 Menopause and breast cancer risk. J Nat Cancer Inst. 48:605-613.
44. Vassilopoulou-Sellin R, Theriault R, Klein MJ. 1997 Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol. 65:89-93.